Q2 25 EPS
$0.17
MISS 25.83%
Est. $0.23
Q2 25 Revenue
$544.8M
MISS 1.31%
Est. $552.0M
vs S&P Since Q2 25
-55.0%
TRAILING MARKET
HIMS -35.3% vs S&P +19.7%
Market Reaction
Did HIMS Beat Earnings? Q2 2025 Results
Hims & Hers Health posted a mixed second quarter, delivering explosive top-line growth while falling short on both profit and revenue expectations. The telehealth company reported Q2 2025 revenue of $544.83 million, up 72.6% year-over-year but traili… Read more Hims & Hers Health posted a mixed second quarter, delivering explosive top-line growth while falling short on both profit and revenue expectations. The telehealth company reported Q2 2025 revenue of $544.83 million, up 72.6% year-over-year but trailing the $552.05 million consensus estimate by 1.31%, while earnings per share of $0.17 missed the $0.23 consensus by 25.83%, weighed down in part by gross margin compression tied to the company's fast-growing but lower-margin weight loss offerings. Subscriber count hit a record 2.4 million, up 31% annually, and net income climbed to $42.51 million from $13.30 million a year ago. The period also saw the acquisition of European digital health provider ZAVA Global, which management expects to contribute at least $50 million in revenue through year-end. The company reaffirmed full-year 2025 guidance of $2.30 billion to $2.40 billion in revenue, though the backdrop darkened somewhat as securities class action lawsuits emerged following Novo Nordisk's termination of its collaboration with the company over compounding practices.
Key Takeaways
- • 73% year-over-year revenue growth driven by new weight loss offerings and continued sustainable growth across existing offerings
- • Subscribers grew 31% year-over-year to over 2.4 million
- • Monthly online revenue per average subscriber grew 30% YoY to $74
- • Nearly 70% of new Q2 subscribers utilized personalized treatment plans
- • Marketing leverage improved with GAAP marketing expenses declining from 46% to 40% of revenue
- • Adjusted EBITDA more than doubled year-over-year to $82.2 million
- • Subscribers utilizing personalized treatment plans for multiple conditions increased nearly 170% year-over-year to over 500 thousand
HIMS YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
HIMS Revenue by Segment
With YoY comparisons, source: SEC Filings
HIMS Revenue by Geography
With YoY comparisons, source: SEC Filings
“It's never been more clear that we are delivering exactly what millions of people have been waiting for: access to personalized, high-quality care that meets people where they are. From the momentum of our business to the results our customers are achieving, we are more confident than ever that our model is helping people optimize their health and realize the benefits of precision medicine.”
— Andrew Dudum, Q2 2025 Earnings Press Release
HIMS Earnings Trends
HIMS vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
HIMS EPS Trend
Earnings per share: estimate vs actual
HIMS Revenue Trend
Quarterly revenue: estimate vs actual
HIMS Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $0.03 | $-0.40 | -1,266.18% | $608.1M | -1.42% |
| Q4 25 BEAT FY | $0.04 | $0.08 | +92.31% | $617.8M | +0.09% |
| FY Full Year | $0.47 | $0.51 | +8.46% | $2.35B | +0.03% |
| Q3 25 MISS | $0.10 | $0.06 | -41.00% | $599.0M | +3.30% |
| Q2 25 MISS | $0.23 | $0.17 | -25.83% | $544.8M | -1.31% |
| Q1 25 MISS | $0.23 | $0.20 | -12.32% | $586.0M | +8.84% |
| Q2 22 MISS | $-0.09 | $-0.10 | -11.11% | $113.6M | +9.32% |